Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 1 September 2017

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

FIT Biotech Oy    

Published: 15:00 CEST 01-09-2017 /GlobeNewswire /Source: FIT Biotech Oy / : FITBIO /ISIN: FI4000148606

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

 

FIT Biotech Oy

 

Company release September 1, 2017 at 4:00 pm

 

FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants

 

On September 26, 2016, the Board of Directors of FIT Biotech Oy (hereinafter also the "Company") decided to establish Convertible Note and Warrant Programmes in order to implement the Convertible Notes with Warrants Funding Programme of up to EUR 12,480,000 between the Company and Bracknor Investment.

 

The Company's Board of Directors decided yesterday to withdraw an ninth tranche of EUR 250,000 included in the Programme and to issue to Bracknor a total of 250 Convertible Notes and 6,024,096 Warrants, which entitle to subscribe for the Company's K shares in accordance with the Terms and Conditions of the Convertible Notes and the Warrants.

 

FIT BIOTECH OY

 

Board of Directors

 

For further information:

Chairman of the Board of Directors Rabbe Slätis

Tel: +358 40 8406749

E-mail: rabbe.slatis@fitbiotech.com

 

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

 

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

 

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

 

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

 

DISTRIBUTION:

NASDAQ OMX Helsinki

Principal media





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: FIT Biotech Oy, Biokatu 8, Tampere FI-33520, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.